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Dans la prise en charge des maladies oncologiques, la priorité est évidemment d'assurer le 
contrôle de la maladie (soit le taux de récidive local et la survie globale), surtout lorsque 
celle-ci est diagnostiquée tôt, à un stade précoce. Cependant, lorsque la maladie est plus 
avancée et que ce contrôle ne peut être assuré de façon raisonnable, l'accent de la prise en 
charge est surtout axé sur le confort du patient. Le principe est de fournir à celui-ci, dans la 
mesure du possible, une qualité de vie acceptable, avec notamment des douleurs bien 
contrôlées. 
Dans le cadre de ce travail de thèse, nous nous sommes intéressés à la prise en charge 
palliative des lymphomes non hodgkiniens (LNH) de bas grade. La survie de ces patients peut 
être relativement longue (de 5 à 10 ans selon les séries), cependant, le traitement est 
rarement à visée curative, contrairement aux lymphomes de haut grade, dont la survie est 
bien moindre, mais avec une chance de guérison après un traitement intensif. 
Plusieurs études cliniques, à la fois prospectives et rétrospectives, ont démontré l'intérêt 
d'une irradiation à faible dose {2x2 Gy) lors d'atteintes lymphomateuses à l'origine de 
symptômes gênants (douleurs, compression par une masse, dyspnée, entre autres). Etant 
donné la facilité d'administration de ce traitement (seulement 2 séances de radiothérapie 
sont nécessaires), et sa quasi absence de survenue d'effets secondaires avec cette faible 
dose totale (4 Gy), nous avons voulu y apporter une contribution suisse. 
Notre étude rétrospective a permis d'inclure 43 patients entre le CHUV et les HUG. Les 
résultats que nous avons obtenus sont également dans la ligne des autres études parues, 
avec un excellent contrôle local, soit un soulagement rapide et durable des symptômes dans 
la majorité des cas. 
Nous espérons que ce travail de thèse, publié sous forme d'un article dans« International 
Journal of Radiation Oncology, Biology, Physics », permettra une prise en charge plus 
optimale des ces patients en leur apportant un traitement facile à administrer, efficace, sans 
effets secondaires dans la majorité des cas, et pouvant être répété un grand nombre de fois 
si nécessaire. 
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CLINICAL INVESTIGATION 
LOW-DOSE RADIOTHERAPY IN INDOLENT LYMPHOMA 
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RENÉ 0. MIRIMANOFF, M.D.,* DAMIEN C. WEBER, M.D} AND MAHMUT ÜZSAHIN, M.D., PH.D.* 
Departments of Radiation Oncology of the *Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, and tuniversity Hospital 
of Geneva, Switzerland 
Purpose: To assess the response rate, duration of response, and overall survival after low-dose involved-field ra-
diotherapy in patients with recurrent Iow-grade lymphoma or chronic lymphocytic leukemia (CLL). 
Methods and Materials: Forty-three (24 women, 19 men) consecutive patients with indolent lymphoma or CLL 
were treated with a total dose of 4 Gy (2 x 2 Gy) using 6- 18-MV photons. The median age was 73 years (range, 
39-88). Radiotherapy was given either after (11=32; 75%) or before (11=11; 25%) chemotherapy. The median time 
from diagnosis was 48 months (range, 1-249). The meclian follow-up period was 20 months (range, 1-56). 
Results: The overall response rate was 90%. Twelve patients (28%) had a complete response, 15 (35%) had 
a partial response, 11 (26 % ) had stable disease, and 5 (11 % ) had progressive disease. The median overall survival 
for patients with a positive response (complete response/partial response/stable disease) was 41 months; for 
patients with progressive disease it was 6 months (p = 0.001). The median time to in-field progression was 21 months 
(range, 0-24), and the median time to out-field progression was 8 months (range, 0-40). The 3-year in-field control 
was 92 % in patients with complete response (median was not reached). The median time to in-field progression was 
9 months (range, 0.5-24) in patients with partial response and 6 months (range, 0.6-6) in those with stable disease 
(p < 0.05). Younger age, positive response to radiotherapy, and no previous chemotherapy were the best factors 
influencing the outcome. 
Conclusions: Low-dose involved-field radiotherapy is an effective treatment in the management of patients with 
recunent low-grade Iymphoma or CLL. © 2011 Elsevier Inc. 
Indolent lymphoma, Palliation, Radiotherapy. 
INTRODUCTION 
Low-grade non-Hodgkin lymphoma (NHL) and chronic lym-
phocytic leukemia (CLL) occur with dramatically increasing 
frequency, with about 23,400 new cases annually in the 
United States ( 1, 2). Whereas Stage I and II disease can be 
treated with radical intent using radiation doses of 25-40 
Gy or/and chemotherapy with a 10-year disease-free survival 
rate of 50%; 80% of ail patients with indolent NHL present 
with advanced Ann-Arbor Stage III or IV (3, 4). Although 
such disseminated indolent NHL is considered to be 
incurable, patients have a relatively long life expectancy, 
with a median survival ranging from 6 to 10 years (4, 5). 
Treatment is therefore directed toward palliation in case of 
symptomatic disease due to progression, compression of 
a vital organ by a bulky mass, or cytopenia. 
Many systemic therapy options such as chemotherapy (6, 
7) and/or immunotherapy (8-10) are available for these 
patients, but, given the high radiation sensitivity through 
apoptosis ( 11- l 3) and the indolent course of this disease, 
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involved-field radiotherapy (IFRT) has proved to be highly 
attractive as a palliative treatment (14). Moreover, many 
trials have shown that high response rates and durable remis-
sion can be achieved with very low-dose (4 Gy) limited-field 
RT (15-21). 
Another option in Stage I follicular lymphoma can be 
a wait-and-see policy, which does not seem to modify the 
prognosis in these patients (22). 
The objective of this retrospective study was to assess the 
response rate, duration of response, and overall survival 
(OS) after IFRT in patients with recurrent low-grade NHL 
or CLL treated in two Swiss centers. 
METHODS AND MATERIALS 
Patients' characteristics 
A total of 43 consecutive patients with low-grade NHL or CLL 
were treated between June 2001 and May 2008 with low-dose 
(2 x 2 Gy) IFRT. Ali patients had histologically confirmed disease, 
which had been stagecl with computed tomography, bone-marrow 
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biopsy, and/or positron emission tomography as appropriate. Of 
these patients, 25 were treated in Geneva and 18 in Lausanne. 
The patients' characteristics are summarized in Table l. 
The median age was 73 years (range, 39-88 years). There were 24 
women and 19 men. Twenty-six patients (60%) hadStage IV disease 
(including CLL), 10 patients (23%) Stage III, 5 patients (12%) Stage 
II, and 2 patients (5%) Stage I. Thirty percent presented with CLL, 
39% with follicular lymphoma, and 31 % with mantle, marginal 
zone, or mucosa-associated lymphoma tissue lymphoma. 
Eighteen patients ( 42%) had head-and-neck (HN), thoracic (T) or 
abdominal (A) disease. Ten patients (23%) had Tand A disease, 2 pa-
tients (5%) hadHN andAdisease, 8 patients (18%) hadHN disease, 3 
patients (7%) had A disease, and 2 patients (5%) had T disease only. 
Twelve patients (28%) had high lactate dehydrogenase (LDH) 
levels. In 72% of patients, the LDH levels were normal or unknown. 
Preirradiation treatments 
In 32 of the 43 patients (75% ), a median of four cycles of chemo-
therapy (range, 0-16 cycles) preceded low-dose IFRT. For 11 ofthese 
patients (25%), low-close IFRT was the first therapy they receivecl. 
Table 1. Patient characteristics 
Characteristic Il= 43 % 
Age (y) 
<73 16 37 
?.73 27 63 
Sex 
M 19 44 
F 24 56 
Anatomie site 
THA 18 42 
TA 10 23 
H 8 18 
A 3 7 
T 2 5 
HA 2 5 
Stage 
1 2 5 
II 5 12 
III 10 23 
IV (inclucling CLL) 26 60 
Pathology 
CLL 13 30 
Follicular Gracie I/II/III 17 39 
Mantle, marginal, or MALT 13 31 
LDH 
High 12 28 
N ormal/unknown 31 72 
Bcl-2 
High 16 37 
N ormal/unknown 27 63 
B2m 
High 13 30 
N ormal/unknown 30 70 
Prior chemotherapy 
0 cycles 11 26 
Median 4 cycles 32 74 
Rituximab 
y 29 68 
N 14 32 
Abbreviatio11s: T = thorax; H = head and neck; A = abdomen; 
CLL = chronic lymphocytic leukemia; MALT = mucosa-
associatecl lymphoma tissue; LDH = lactate clehyclrogenase; 
B2m= beta-2 microglobulin. 
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Table 2. Univariate analyses for prognostic factors. 
3-year in-field 95% p 
Variable Il =43 contrai(%) CI value 
Age (y) 
?.73 28 36 10-62 0.08 
<73 15 50 28-72 
Sex 
M 19 45 20-70 0.69 
F 24 42 18-66 
Site 
THA 18 24 22-70 0.64 
TA 10 34 0-55 
H 8 36 33-100 
A 3 53 0-86 
T 2 100 
HA 2 68 0-100 
Stage 
I 2 100 0.41 
II 5 53 4-100 
III 10 60 30-90 
IV 26 30 8-52 
Pathology 0.63 
Mantle + 9 36 0-72 
follicular G3 
Other 34 47 28-66 
LDH 
High 12 28 1-55 0.15 
Normal/unknown 31 52 30-74 
Bcl2 
High 16 49 10-78 0.74 
N ormal/unknown 27 42 20-64 
B2m 
High 13 35 9-79 0.68 
N ormal/unknown 30 45 20-70 
Prior chemotherapy 
0 11 69 40-98 0.13 
4 32 34 13-55 
Rituximab 
y 29 39 17-60 0.49 
N 14 55 25-85 
Abbreviations: T = thorax; H = heacl and neck; A = abdomen; 
LDH = lactate clehyclrogenase, B2m = beta-2 microglobulin; 
Bc12 = B-cell lymphoma 2 gene. 
Twenty-nine patients (68%) receivecl rituximab before irradiation. 
The median time between chemotherapy or rituximab and radiation 
therapy was 7 months (mean, 15 months; range, 1-120 months). 
Radiation techniques 
The RTwas deliverecl using either a telecobalt unit or a linear ac-
celerator. Treatment planning consistecl of either two-dimensional 
or three-climensional conformai RT. The patients receivecl a total 
close of 4 Gy in two fractions, given once claily over 2 to 4 clays. 
The RT was appliecl only to the involvecl site or to the affected 
lymph nodes with a 2-cm margin. Megavoltage photon beams of 
6 to 18 MV or gamma beams were usecl. 
Endpoints and statistical methods 
The primary enclpoint of the stucly was time to in-field progres-
sion. The OS and time to local (in-field) or distant (out-field) pro-
gression were calculated accorcling to the Kaplan-Meier methocl 
(23). The duration of response for each irradiatecl site was calculatecl 
from the start of RT to the first clocumentecl clisease progression. 
Confidence intervals (CI) were computed from standard errors. 
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Fig. l. (a) Mucosa-associated lymphoma tissue lymphoma of the right parotid gland, before radiation therapy. (b) After 
radiation therapy, 2 Gy in two fractions, complete response. 
Objective responses were assessed clinically or radiologically ac-
cording to the Response Evaluation Criteria in Solid Tumors criteria 
(24). The first evaluation was performed 6 weeks after the end of 
treatment and subsequent evaluations every 3 to 6 months. A 
complete response (CR) was defined as a complete disappearance 
of clinically or radiologically detectable disease within the treatment 
field; a partial response (PR), as a decrease of at least 30% in the sum 
of diameters of target lesions. Stable disease (SD) was defined as 
neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD. Only patients with PD with at least 20% increase in 
the sum of diameters of the target lesions (PD) were considered as 
nonresponders. Toxicity was scorecl accorcling to the toxicity scale 
of the National Cancer Institute Common Terminology Criteria 
for Adverse Events 3.0 (25). Multivariate analysis was clone using 
the Cox stepwise regression methocl to cletermine the inclepenclent 
contribution of each prognostic factor (26). 
RESULTS 
The median follow-up period was 20 months (range, 1-
56), and the median time since diagnosis was 48 months 
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Fig. 2. Overall survival (solicl line), in-field control (clottecl line), 
and clisease control out of irradiatecl volume ( clashed dotted line) 
in 43 patients with indolent lymphoma or chronic lymphocytic 
leukemia (median overall survival, 30 months; median in-field 
control, 21 months; meclian out-field control: 8 months). 
(range, 1-249 months). Ail patients completed their 
treatment. Among the 43 patients, 13 (30%) had a CR, 17 
(40%) had a PR, and 7 (16%) presented with SD after irradi-
ation. Only 6 patients (14%) had PD. Figure 1 shows 
selected clinical images of 1 patient who had a CR after 
receiving 4 Gy IFRT. The median overall survival was 30 
months. The median time to in-field progression was 21 
months (range, 0-24 months), and the median time to 
out-field progression was 8 months (range, 0-40 months) 
(Fig. 2). The actuarial 3-year freedom from in-field local 
progression was 92% (95% CI, 76-100) for patients with 
a CR. The response to low-dose IFRT in cases of indolent 
lymphoma was also highly predictive for the OS, with a p 
value of 0.0013 (Fig. 3). 
Univariate analyses were performed to determine which 
factors were predictive of in- field control (Table 2). Age 
(<73 vs. 273 years) seemed to predict response without 
reaching statistical significance (p = 0.083) (Fig. 4). Other 
prognostic factors for in-field contrai (i.e., sex, number 
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Fig. 3. Overall survival accorcling to symptomatic response in 43 
patients with indolent lymphoma or chronic lymphocytic leukemia. 
Solicl line = complete response (CR) + partial response (PR) + 
stable clisease (SD); dotted line =progressive disease (PD). Median 
survival for positive response (CR, PR, and SD) = 41 months; me-
dian survival for negative response (PD)= 6 months; p = 0.0013. 
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Fig. 4. In-field control according to age in 43 patients with indolent 
lymphoma or chronic lymphocytic leukemia. Median in-field con-
trol = 5 months for age ?.73 years (dotted line) vs. 24 months for 
age <73 years (solid line), p = 0.0833. 
and history of systemic therapies, stage and grade of the dis-
ease, number of sites, presence of bulky disease, bcl2 over-
expression, and LDH rates) could not be distinguished in 
these patients. 
In multivariate analysis, younger age ( <73 years was 
better) and previous chemotherapy (no chemotherapy was 
better) independently inftuenced in-field contrai with IFRT 
(relative risk = 1.79, p = 0.02 for age; and relative risk = 
1.96, p = 0.02 for prior chemotherapy). 
Toxicity was minimal or absent except for Grade 1-2 
nausea in 2 patients irradiated on the upper abdomen. 
DISCUSSION 
The results of the present study using a total dose of 4 Gy 
in two fractions showing an overall response rate of 90% are 
in agreement with previous reported data. Girinsky et al. 
( 18) and Johannsson et al. (19) showed an overall response 
rate of 81 % and 82%, respectively (Table 3). The slight dif-
ference may be because we considered patients with stable 
Volume 1111, Number Il, 2011 
disease (26%) to be responders, unlike either of the other 
authors. Our complete response rate, however, was only 
28%, compared to 55-61 % reported in the other series. lt 
is important to point out that our patients may have been 
in worse general condition: the median age in our series 
was 73 years, significantly higher than in the Dutch (62 
years) (27) or French (59 years) (18) studies. Moreover, in 
the French series ( 18), the patients had a short disease history 
and more favorable outcomes; only 31 % of them presented 
with Stage IV disease compared with 60% in ours. In our 
series, patients were often referred to our department after 
a long course of disease and multiple chemotherapies. 
Regarding the prognostic factors, very few of them could 
be already reported in the literature. In our series, older age 
("2:.73 years) and previous chemotherapy were the worst 
prognostic factors regarding the benefit of such irradiation. 
The median in-field disease control was 5 months vs. 24 
months for patients older vs. younger than 73 years, respec-
tively. Patient age was also reported as an adverse factor by 
Girinsky et al., with a cutoff value of 65 years (18). These 
authors proposed to increase the dose per fraction from 2 
to 3 Gy in the older age groups to extend the efficacy of 
the local treatment. The same team confirmed the significant 
influence of the number of chemotherapy regimens on 
2-year freedom from local progression (96% vs. 48% for 
0-1 cycles vs. 2 or more cycles). In our series, the 4-year 
in-field control rate was 70% (median was not reached) for 
patients not receiving chemotherapy before irradiation, and 
the median 9 months for those who received chemotherapy 
(with a median of four cycles). However, in the prospective 
trial by Haas et al. (27), which included 109 patients and 304 
irradiated sites with this protocol, neither CR nor overall 
relative risk was associated with age or the number of previ-
ously administered chemotherapy regimens. 
Girinsky et al. ( 18) reported that a bulky tumor >5 cm in 
diameter was an important adverse factor regarding the 
efficacy of low-dose IFRT (CR in 29% of patients vs. 
58% ). ln the prospective trial by Haas et al. (27), a p value 
of borderline clinical significance was found for the 
Table 3. Selected studies reporting the use of low-dose involved-field radiotherapy in non-Hodgkin lymphoma 
Follicular CT Median time 2-y Median 
No. of patients Median histology Bulky given from diagnosis CR PR Ove rail Median FFLP time to LP 
Study and sites age (y) (%) (%) (%) toRT (%) (%) RR(%) FU (mo) (%) (mo) 
Ng et al. (21) 10 (14 sites) 70 10 NR 90 32.5 70 20 90 6.5 NR 6 
Girinsky 48 (135 sites) 59 67 21 94 32.4 57 24 SI 54 56 47 
et al. (18) 
Johannsson 22 (31 sites) 62 59 39 NR NR 55 22 82 8 NR 22 
et al. (19) 
Sawyer and 11 (16 sites) 75 55 69 73 Mean 44 38 56 94 NR NR 5 
Timothy ( 17) 
Haas et al. (27) 109 (304 sites) 62 90 44 94 44 61 31 92 NR 33 25 
Luthy et al. (20) 33 (43 sites) 52 85 29 52 "43 84 12 95 NR NR 4 
Current study 43 73 39 37 75 48 30 40 86 20 45 21 
Abbreviations: CT = computed tomography; RT =radiation therapy; CR= complete response; PR= partial response; RR = response rate; 
FU = follow-up; FFLP = freedom from local progression; LP = local progression; NR = not reported. 
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difference in CR rates between patients with nodal size :=;,7 
cm and patients with larger nodes. A recent North American 
series by Luthy et al. (20) of 33 patients found similarly that 
the likelihood of achieving a CR was influenced by sites with 
a higher response in the head-and-neck areas and for disease 
size <4 cm. In our series, the median tumor size was 46.5 mm 
and the mean value was 67 mm. Inasmuch as we have not 
found a uniform definition for bulky disease in the literature, 
we have tried two different cutoff values. Using a cutoff 
value of 50 mm, the time to in-field progression was 24 
months for nonbulky disease and 6 months for bulky disease, 
with a p value ofü.37. Therefore, a cutoff value of 50 mm did 
not seem to be significant. By contrast, with a cutoff value of 
100 mm, the time to in-field progression was 24 months for 
nonbulky disease and 3 months for bulky disease, with a p 
value of 0.032. Therefore, we can assert, in our series, that 
a bulky disease of more than 100 mm predicts local failure. 
Histologie characteristics have also been shown to 
influence the benefit of such a treatment. Patients with 
CLL/small lymphocytic lymphoma were Jess likely to 
achieve CR in the prospective Danish trial ( 19) than were 
patients with follicular lymphomas (74 vs. 29%). In our 
series, 39% of the patients had a follicular histology, and 
among them, 7% presented a Grade 3 lymphoma, which 
could be a borderline indication for a low-dose IFRT. We 
also included mantle zone lymphomas. This point could 
also explain in part our moderate CR rate. We also observed 
that the overall OS was higher for patients with follicular 
lymphoma Grade 1 or 2 than for mantle and follicular Grade 
3 disease (p = 0.013). This seems to reflect the biologie ag-
gressiveness of the disease, but it did not affect the local 
control after 2 x 2 Gy, which was the aim of our study. 
In view of these results, we also wonder if this simple 
treatment could not be an indication in selected higher-
grade lymphomas (for example, diffuse large B cell 
lymphoma), especially for older patients with multiple 
comorbidities who are not able to tolerate chemotherapy 
or more aggressive treatments. One study ( 15) has already 
confirmed that good palliation can be obtained in these 
difficult situations. If the treatment does not work or if its 
effect does not last, it can be repeated many times or can 
be replaced by a longer course of irradiation. 
Our results confirm that low-dose IFRT remains a very 
effective, simple, long-lasting, and cost-effective palliative 
treatment for patients with advanced-stage or recurrent indo-
lent NHL. However, achieving CR could be more difficult in 
elderly patients with refractory lymphomas after multiple 
chemotherapy regimens. Therefore, we encourage hematol-
ogists, oncologists, and other physicians to refer their 
patients earlier in the course of the disease. 
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